Chronic liver disease (CLD) is a slow and silent killer.  It is widespread with about 15% prevalence worldwide. About 32,000 people die each year in the US from liver disease. Much improvement is needed in the management of liver disease, especially due to the national focus on healthcare accountability and cost containment. 

Injury to the liver (from infections, alcohol, tumors and fat buildup) leads to scar tissue (“fibrosis”) that can reduce liver function. However, the liver has the ability to regenerate thus mitigating the damage. The amount of liver function remaining is determined by the net effect of fibrogenesis and regeneration. It is the residual liver function that determines disease outcomes. Measuring fibrosis alone is not enough!

The HEPATIQ test measures liver function. This is essential for therapy planning and predicting adverse outcomes including liver transplantation. HEPATIQ provides 3 indices of disease severity - PHM, fSV and fLV. These indices identify patients at risk for future decompensation, and patients with adequate hepatic reserve who would have benign outcomes. Patients with low PHM have a 15-fold increase in risk for hepatic decompensation or liver-related death.

HEPATIQ has been cleared by the FDA for sale in the U.S.A.

For more information, please contact:
      Dipu Ghosh, MSEE, MBA.
      Chief Executive Officer
      John Hoefs, MD.
      Chief Operating Officer